Genus plc
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Semi-annual Revenue
•
in mil. unless spec.Semi-annual Earnings Per Share
•
in mil. unless spec.Semi-annual Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Jorgen Kokke
- Full Time Employees
- 3,054
- Sector
- Process industries
- Industry
- Agricultural commodities/Milling
- Address
- Matrix House Basingstoke HM United Kingdom RG21 4FF
- IPO Date
- Jul 6, 2000
- Website
- genusplc.com
- Similar Companies
- Business
- Genus plc is a United Kingdom-based global animal genetics company specializing in the development and sale of genetically superior breeding stock and related products to the livestock farming industry. The company operates primarily through two business units: ABS, which focuses on dairy and beef cattle genetics, providing bovine genetics products such as bull semen and embryos to farmers for artificial insemination; and PIC, which focuses on porcine genetics, supplying genetically superior breeding pigs and semen to pork producers. Genus markets its products and services across 30 countries, covering six continents, and reaches an additional 50 markets via distribution partners. It serves the dairy, beef, and pork food production sectors by applying biotechnology and advanced breeding technologies to enhance animal productivity, profitability, and sustainability. Founded in 1994 and headquartered in Basingstoke, England, Genus plc is a constituent of the FTSE 250 Index. Genus’s product portfolio includes superior cattle genetics under the ABS brand and genetically enhanced pig genetics under the PIC brand. The company supports its customers with cutting-edge science and technology to breed animals with improved traits that yield more milk and meat efficiently while reducing environmental impact. In addition to genetics sales, Genus invests heavily in research and development, with an annual investment exceeding GBP 20 million, emphasizing sustainable animal breeding innovations. Recent major company developments include taking full operational control of its De Novo joint venture to strengthen its genetic supply chain, notably within bovine genetics. The company is advancing a multi-phase Value Acceleration Programme (VAP) aimed at boosting profitability and growth in its ABS business, with Phase 2 generating substantial operating profit benefits and Phase 3 planning underway. PIC has significantly expanded its customer base in China with new royalty agreements secured, and the company achieved FDA procedural progress with site inspections for its PRRS-resistant pig products, expecting approval during 2025. These strategic initiatives reflect Genus’s commitment to accelerating growth, enhancing operational efficiency, and expanding market reach globally. Overall, Genus plc operates in the biotechnology-driven livestock genetics industry providing high-value genetic materials and breeding services that help farmers worldwide improve animal productivity and sustainability in dairy, beef, and pork production. It leverages advanced genetic research and global distribution networks to maintain leadership in animal genetics markets. Its developments in 2024-2025 demonstrate focus on operational improvements, regulatory advancements, and expanding its commercial footprint across key geographies.
Company News
Genus H2 Earnings Call Highlights
Genus shares slide despite bumper year and £60m buyback
Genus says its set to beat market expectations
Genus Power Surpasses 26 Million Smart Meter Deployment Worldwide, Reinforcing Leadership in End-to-End Advanced Metering Solutions
Genus plc (GENSY) Q2 2026 Earnings Call Transcript
Genus growth prospects look healthy, says broker
Bank lifts Genus target to 3300p on strong PIC trading in China and Latin America
UK animal genetics firm Genus surges on annual profit forecast upgrade
Genus extends Friday rally as brokers lift forecasts after ahead-of-expectations update
Genus (OTCMKTS:GENSF) Trading 5.1% Higher – Still a Buy?
Genus boosts shares by raising profit outlook after strong China pig sales
Genus Plc (GENSY) Q4 2025 Earnings Call Prepared Remarks Transcript
Genus jumps 11% as new Chinese pig JV formed at end of 'landmark' year
British animal genetics firm Genus surges on strong annual profit growth
Broker lifts target price for Genus as turnaround gathers pace
Genus up 7% after strong trading update; broker reckons there's further to go
Genus FDA green light a “hugely significant landmark"
UK's Genus secures FDA approval for PRP gene edit; shares soar
Genus shares leap 22% after FDA clears gene-edited pigs for US food chain
Genus plc (GENSF) Q2 2025 Earnings Call Transcript